Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer

Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer

Abstract. Background:. Durvalumab after chemoradiotherapy (CRT) failed to bring survival benefits to patients with epidermal growth factor receptor (EGFR) mutations in PACIFIC study (evaluating durvalumab in patients with stage III, unresectable NSCLC who did not have disease progression after conc...

Full description

Saved in:
Bibliographic Details
Main Authors: Xin Dai, Qian Xu, Lei Sheng, Xue Zhang, Miao Huang, Song Li, Kai Huang, Jiahui Chu, Jian Wang, Jisheng Li, Yanguo Liu, Jianyuan Zhou, Shulun Nie, Lian Liu, Jing Ni
Format: Article
Language:English
Published: Wolters Kluwer 2025-07-01
Series:Chinese Medical Journal
Online Access:http://journals.lww.com/10.1097/CM9.0000000000003386
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://journals.lww.com/10.1097/CM9.0000000000003386

Similar Items